Related Experiment Video

Updated: May 15, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination

H Tang1, P Sampath, X Yan

  • 1Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.

Gene Therapy
|January 4, 2013
PubMed

Insights

Doxycycline enhances anti-tumor immunity by increasing tumor cell susceptibility to immune cells and oncolytic viruses. This drug shows promise for improving adoptive immune cell and viral therapies against cancer.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumors evade immune detection by downregulating NKG2D ligands (MICA/B).
  • Matrix metalloproteinases (MMPs) cleave MICA/B, reducing immune cell recognition.
  • Adoptive immune cell therapies face challenges due to tumor evasion strategies.

Purpose of the Study:

  • To investigate doxycycline's effect on MICA/B expression and tumor cell susceptibility.
  • To evaluate doxycycline's impact on oncolytic vaccinia replication and efficacy.
  • To assess the combined efficacy of doxycycline with CIK-oncolytic vaccinia therapy.

Main Methods:

  • Treatment of human tumor cells with doxycycline.
  • Analysis of MICA/B shedding and cell surface expression.
  • Assessment of tumor cell sensitivity to CIK cells.
  • Evaluation of oncolytic vaccinia replication in tumor cell lines.
  • Testing combination therapies in vitro.

Main Results:

  • Doxycycline blocked MICA/B shedding and increased its cell surface expression.
  • Tumor cells showed enhanced susceptibility to CIK cells after doxycycline treatment.
  • Doxycycline selectively enhanced oncolytic vaccinia replication and tumor cell sensitivity.
  • Combination therapy with doxycycline, CIK, and oncolytic vaccinia demonstrated increased anti-tumor effects.

Conclusions:

  • Doxycycline exhibits pleiotropic anti-tumor effects by enhancing both immune cell and oncolytic viral therapies.
  • Doxycycline's ability to stabilize NKG2D ligands and boost viral replication makes it a promising candidate for clinical trials.
  • This study highlights doxycycline as a potential adjuvant therapy to overcome tumor immune evasion.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...